telmisartan has been researched along with Disease Models, Animal in 150 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 28 (18.67) | 29.6817 |
| 2010's | 98 (65.33) | 24.3611 |
| 2020's | 24 (16.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alexopoulos, SJ; Beretta, M; Chen, SY; Garcia, CJ; Hargett, SR; Hoehn, KL; Murray, JH; Olzomer, EM; Salamoun, JM; Santos, WL; Shah, DP; Tucker, SP | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Alfuraih, BS; Alsuhaibani, NA; Elsayed, AM; Mahmoud, RH; Nadwa, EH; Rashed, LA; Said, ES | 1 |
| Bilen, A; Celik, M; Celik, Z; Gulaboglu, M; Halici, Z; Kul, A; Kutlu, Z; Maman, A | 1 |
| Choi, EY; Choi, IS; Jeon, SJ; Keum, BR; Kim, SJ; Lee, Y | 1 |
| Abraham, SJK; Dedeepiya, VD; Ikewaki, N; Iwasaki, M; Levy, GA; Preethy, S; Raghavan, K; Ranganathan, N; Senthilkumar, R; Srinivasan, S; Yamamoto, N | 1 |
| Kreple, CJ; Miller, TM; Racette, BA; Schoch, KM; Searles Nielsen, S; Shabsovich, M; Shen, T; Song, Y | 1 |
| Cao, HM; Deng, Y; Duan, R; Fu, XX; Jiang, T; Lian, HW; Wei, B; Zhang, YD | 1 |
| Cao, TT; Chen, HH; Guo, W; Lu, R; Shan, XL; Tian, J; Wang, SN; Xu, M; Zhang, C; Zhao, P; Zheng, JL | 1 |
| Cho, DH | 1 |
| Abd El-Latif, AM; Abdelkader, NF; Khattab, MM | 1 |
| Hasanin, AH; Mohamed, RH | 1 |
| Finger, S; Garlapati, V; Karbach, SH; Knopp, T; Knorr, M; Kossmann, S; Lagrange, J; Molitor, M; Münzel, T; Nguyen, TS; Rudi, WS; Ruf, W; Schüler, R; Wenzel, P; Wild, J | 1 |
| Li, P; Li, Z; Ma, Q; Peng, Y; Zhang, X | 1 |
| Hazlewood, RJ; Kuchtey, J; Kuchtey, RW; Wu, HJ | 1 |
| Hosoda, A; Kohno, T; Masamichi, S; Matsumoto, Y; Toriyama, Y; Tsuji, T; Yoshida, Y | 1 |
| Dong, JH; Guo, JH; Li, YY; Liu, YQ; Zhu, CH | 1 |
| Chen, W; Dang, C; Diao, D; Li, M; Wang, Y; Xie, X; Zhang, X | 1 |
| Aguirre, MV; Ferrer, EG; Lima, AM; Martínez, VR; Stergiopulos, N; Todaro, JS; Williams, PA | 1 |
| Hövener, JB; Huber, G; Huber, L; Jurk, D; Matschl, U; Ogrodnik, M; Peschke, E; Raasch, W; Schwaninger, M; Stölting, I; Wenzel, J; Will, O | 1 |
| Ameen, O; Motawea, SM; Naguib, YM; Rizk, MS; Samaka, RM | 1 |
| Arya, DS; Bhatia, J; Garg, S; Kaur, P; Khan, SI; Kumar, M; Malhotra, RK; Nag, TC; Ray, R; Sharma, MK | 1 |
| Beckmann, L; Busch, H; Freitag, M; Freschi, ML; Fuchs, B; Galuska, CE; Hirose, M; Huber, G; Ibrahim, SM; Knobloch, JK; Künstner, A; Langan, EA; Matschl, U; Raasch, W; Stölting, I | 1 |
| Li, ZX; Song, XR; Wang, FZ; Zhang, Z | 1 |
| Cai, Y; Chang, D; Ju, S; Lu, CQ; Min, SD; Wang, YC; Xu, TT; Zhang, SJ; Zhao, Z | 1 |
| Asraf, K; Cohen, H; Fleisher-Berkovich, S; Torika, N | 1 |
| Dalman, RL; Fujimura, N; Michie, SA; Miyata, M; Tanaka, H; Wang, W; Xu, B; Xuan, H | 1 |
| Gu, Y; Körbel, C; Laschke, MW; Menger, MD; Nenicu, A | 2 |
| Gao, P; Li, Q; Lin, S; Liu, D; Lu, Z; Wang, B; Wei, X; Xia, W; Xiong, S; Zhao, Z; Zhu, Z | 1 |
| Afolayan, O; Anunobi, CC; Ishola, IO; Tijani, KH; Udokwu, VU | 1 |
| Bu, M; Gao, Y; Li, M; Li, W; Liu, Y; Wang, Y; Zhang, J | 1 |
| Dalman, RL; Iida, Y; Miyata, M; Xu, B; Xuan, H | 1 |
| Badea, O; Bejenaru, C; Bejenaru, LE; Cristea, OM; Ionică, FE; Mogoantă, L; Negreş, S | 1 |
| Chen, X; Lin, Y; Luo, W; Shi, Y; Song, A; Wang, W; Zeng, Y; Zhang, Y | 1 |
| Garrido-Gil, P; Kulisevsky, J; Labandeira-Garcia, JL; Lanciego, JL; Pedrosa, MA; Rodriguez-Perez, AI; Sucunza, D | 1 |
| Bhat, A; Chidambaram, SB; Essa, MM; Guillemin, GJ; Mani, S; Manivasagam, T; Rajamani, B; Ray, B; Sekar, S; Thenmozhi, AJ | 1 |
| Cai, JH; Cheng, X; Ewurum, HC; Luo, X; Wang, M; Yang, YY; Zeng, HQ; Zeng, YM; Zhang, XB | 1 |
| Fathy, M; Fawzy, MA; Khalifa, EMMA | 1 |
| Bao, L; Gao, P; Wu, X; Yao, T; Zha, D | 1 |
| Ackley, JC; Andersen, JN; Baddour, J; Blume-Jensen, P; Brady, SW; Chickering, DE; Economides, KD; Ehrlich, DC; Golder, MR; Held, EJ; Huh, SJ; Johnson, JA; Kopesky, PW; Liu, J; Neenan, AM; Nguyen, HV; Paramasivan, S; Reiter, LA; Saucier-Sawyer, JK; Shipitsin, MV; Vangamudi, B; Vohidov, F | 1 |
| Kazdová, L; Kurtz, TW; Landa, V; Mlejnek, P; Pravenec, M; Silhavy, J; Simáková, M; Zídek, V | 1 |
| Kagota, S; Kunitomo, M; Maruyama, K; Nakamura, K; Shinozuka, K; Tada, Y; Wakuda, H | 1 |
| Agarwal, M; Chugh, PK; Gupta, M; Tekur, U | 1 |
| Cynis, H; Demuth, HU; Fujii, M; Haegele, M; Heiser, U; Hoffmann, T; Kehlen, A; Schilling, S; Shibazaki, Y; Yoneyama, H | 1 |
| Liu, Y; Xu, L | 1 |
| Asanuma, K; Fukami, K; Kaida, Y; Kaifu, K; Matsui, T; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S | 1 |
| Attia, YM; El-Khatib, AS; Elalkamy, EF; Hammam, OA; Mahmoud, SS | 1 |
| Behenna, D; Krishnan, S; Prasadarao, NV; Shanmuganathan, MV; Stoltz, BM | 1 |
| Alves, MS; Aragão, KS; Araújo, AA; Araújo, LS; Araújo, RF; Brito, GA; Medeiros, CA; Moura, LM; Souza, TO | 1 |
| Cai, WW; Li, H; Liu, BC; Lu, W; Sun, W; Wang, DL; Wang, PJ; Yu, CP; Zhang, N | 1 |
| Kobara, M; Nakata, T; Ohigashi, M; Toba, H; Wang, J | 1 |
| Abe, T; Aukema, HM; Horie, S; Kugita, M; Nagao, S; Nakanishi, K; Sasaki, M; Yamaguchi, T; Yoshihara, D | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Ikeda, Y; Kamiya, T; Kozuki, M; Kurata, T; Lukic, V; Matsuzono, K; Miyazaki, K; Morimoto, N; Ohta, Y; Wada, D; Yamashita, T | 1 |
| Chang Li, J; Du, GT; Hong, H; Hu, M; Liu, GJ; Long, Y; Mei, ZL; Miao, MX; Wang, C | 1 |
| Frohlich, ED; Susic, D | 1 |
| Abdallah, DM; Al-Shorbagy, MY; Arab, HH; Nassar, NN | 1 |
| Hasegawa, Y; Katayama, T; Kim-Mitsuyama, S; Koibuchi, N; Ma, M; Nakagawa, T; Ogawa, H; Sueta, D; Toyama, K; Uekawa, K | 1 |
| Cakir, M; Calikoglu, C; Demir, R; Halici, Z; Ozdemir, G; Unal, D; Yuksel, TN | 1 |
| Kagota, S; Maruyama, K; McGuire, JJ; Nakamura, K; Shinozuka, K; Wakuda, H; Yoshikawa, N | 1 |
| Chen, JA; Gill, AJ; Gross, S; Jarolimek, W; Pollock, CA; Saad, S; Schilter, H; Wong, M; Wong, MG; Zhang, J | 1 |
| Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G | 1 |
| Deng, Y; Guo, XL; Liu, HG; Liu, K; Shang, J; Yuan, X; Zhu, D | 1 |
| Deng, Y; Guo, X; Liu, H; Shang, J; Yuan, X; Zhu, D | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Omote, Y; Sato, K; Yamashita, T | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kurata, T; Omote, Y; Sato, K; Yamashita, T | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Kurata, T; Liu, W; Yamashita, T; Zhai, Y | 1 |
| Afrin, MR; Arumugam, S; Giridharan, VV; Harima, M; Karuppagounder, V; Miyashita, S; Nakamura, M; Nakamura, T; Nomoto, M; Pitchaimani, V; Sreedhar, R; Suzuki, H; Suzuki, K; Thandavarayan, RA; Watanabe, K | 1 |
| Araújo Júnior, RF; Araújo, AA; Fernandes, D; Guerra, GC; Lira, GA; Melo, MN; Silva, AL; Souto, KK | 1 |
| Liu, Y; Wang, B; Wang, Q; Wang, X; Wang, Y; Yang, Q; Zhang, C; Zhang, Q | 1 |
| Chen, JH; Chen, LL; Chen, XH; Fu, FY; Tang, MR; Wang, WW; Zhang, FL | 1 |
| Chang, CK; Cheng, JT; Lin, CM; Lin, JW; Tsai, JT | 1 |
| Chen, Y; Hao, K; Yu, D | 1 |
| Chan, LK; Chen, L; Cheng, TW; Klein, T; Leung, PS; Zhao, S | 1 |
| Dash, R; Harnish, P; Kim, PJ; McConnell, MV; Nishimura, D; Toma, I; Yang, PC | 1 |
| Jiang, T; Ou, Z; Tong, Q; Wu, L; Zhang, Y; Zhu, D | 1 |
| Adachi, M; Hayata, M; Hirata, S; Kadowaki, D; Kakizoe, Y; Kitamura, K; Miyasato, Y; Miyoshi, T; Mizumoto, T; Morinaga, J; Mukoyama, M; Nakagawa, T; Narita, Y; Sakai, Y; Uchimura, K; Ueda, M | 1 |
| Breitbart, E; Ishai, E; Mendel, I; Shoham, A; Yacov, N | 1 |
| Cuce, G; Erdi, F; Esen, H; Feyzioglu, B; Kalkan, E; Karatas, Y; Kaya, B; Keskin, F; Kilinc, I | 1 |
| Alter, M; Ando, R; Antonenko, V; Chaykovska, L; Hasan, AA; Hocher, B; Klein, T; Okuda, S; Rahnenführer, J; Reichetzeder, C; Sharkovska, Y; Tammen, H; Tsuprykov, O; Ueda, S; von Websky, K; Yamagishi, SI | 1 |
| Brunner, HR; Foster, C; Huo, Y; Michel, MC | 1 |
| El-Kadem, AH; El-Mahdy, NA; El-Sayad, ME | 1 |
| Cai, J; Cheng, S; Gao, L; Li, H; Li, M; Liu, P; Song, Y; Tian, G; Wang, Y; Yang, S; Yin, Y; Zhang, H | 1 |
| Blakely, PK; Huber, AK; Irani, DN | 1 |
| Grzesiak, A; Kaschina, E; Kemnitz, UR; Krikov, M; Schrader, F; Sommerfeld, M; Unger, T | 1 |
| Goto, H; Ishida, S; Kezuka, T; Nagai, N; Okunuki, Y; Takeuchi, M; Usui, Y | 1 |
| Altunkaynak, Z; Gocer, F; Halici, MB; Karaca, M; Keles, ON; Kumtepe, Y; Odabasoglu, F; Polat, B | 1 |
| Burgueño, AL; Carabelli, J; Pirola, CJ; Rosselli, MS; Schuman, M; Sookoian, S | 1 |
| Kanayama, M; Kawai, K; Kudo, H; Mann, DA; Morita, S; Nakayama, Y; Oya, T; Sasahara, M; Sugiyama, T; Takahara, T; Yata, Y | 1 |
| Hori, T; Kawamata, T; Kobayashi, M; Kobayashi, T; Okada, Y; Shibata, N | 1 |
| Horiuchi, M; Iwai, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K | 1 |
| Arora, S; Arya, DS; Goyal, S; Joshi, S; Kumari, S; Mittal, R; Nag, TC; Ray, R | 1 |
| Aini, W; Ebihara, K; Hirata, M; Kusakabe, T; Li, Y; Miyamoto, L; Murray, M; Nakao, K; Rong, X; Zhao, M | 1 |
| Emre, M; Kavak, S; Unlugenc, H | 1 |
| Chander, PN; Charney, DN; Ding, G; Kumar, D; Singhal, PC; Vallabu, S; Yadav, A | 1 |
| Al-Melhim, WN; Al-Sultan, AI; Fouad, AA; Qureshi, HA; Yacoubi, MT | 1 |
| Arora, S; Arya, DS; Bhatt, TK; Das, P; Goyal, S; Kumari, S; Sharma, A | 1 |
| Hirose, H; Kasahara, Y; Matsuyama, T; Nakagomi, T; Nakano, A; Stern, DM; Taguchi, A; Uno, H | 1 |
| Czuczwar, SJ; Jakubus, T; Janowska, A; Tochman-Gawda, A; Łukawski, K | 1 |
| Clemenz, M; Foryst-Ludwig, A; Hartge, M; Hess, K; Kintscher, U; Marx, N; Sprang, C; Unger, T | 1 |
| Kajioka, T; Kitahara, Y; Miura, K; Takeuchi, M; Yamagishi, S | 1 |
| Aizawa, Y; Gurusamy, N; Kodama, M; Ma, M; Rajavel, V; Sukumaran, V; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
| Gu, XF; Liu, AJ; Liu, W; Ma, XJ; Song, SW; Su, DF; Su, FY; Wang, W; Zhang, H | 1 |
| Fujisawa, K; Kuwashiro, S; Matsumoto, T; Nishina, H; Oishi, T; Sakaida, I; Terai, S | 1 |
| Imig, JD; Khan, AH | 1 |
| Guan, HS; Meng, XM; Qiao, SB; Shang, Z; Shangguan, HJ; Yang, L | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Toyama, K; Yasuda, O | 1 |
| Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Sukumaran, V; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 2 |
| Capuano, A; D'Amico, M; Di Filippo, C; Donniacuo, M; Ferraraccio, F; Rinaldi, B; Rossi, F; Sodano, L | 1 |
| Higaki, J; Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Tsukuda, K | 1 |
| Azuma, J; Iekushi, K; Iwabayashi, M; Kusunoki, H; Morishita, R; Okayama, K; Otsu, R; Rakugi, H; Sanada, F; Taniyama, Y | 1 |
| Kobara, M; Nakata, T; Noda, K; Toba, H; Tojo, C; Wang, J | 1 |
| Garrido-Gil, P; Guerra, MJ; Joglar, B; Labandeira-Garcia, JL; Rodriguez-Perez, AI | 1 |
| Ishiguro, H; Komiya, M; Kubota, Y; Long, N; Seeni, A; Shirai, T; Takahashi, S; Tang, M; Uemura, H | 1 |
| Chen, XY; Wan, WY; Wang, WY; Zeng, YM; Zhang, YX | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Shudou, M; Tsukuda, K | 1 |
| Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R | 1 |
| Goyal, BR; Mehta, AA | 1 |
| Cho, ST; Kim, JC; Park, EY | 1 |
| Al-amran, FG; Ali, SJ; Hadi, N; Huntei, NK; Mohammad, BI; Yousif, NG | 1 |
| Alter, ML; Henze, A; Hocher, B; Krause-Relle, K; Kretschmer, A; Ott, IM; Raila, J; Sharkovska, Y; Stasch, JP; Tsuprykov, O; von Websky, K | 1 |
| Hirooka, Y; Kishi, T; Sunagawa, K | 1 |
| Liu, RX; Wen, Y; Yi, ET; Yin, CH | 1 |
| Ganburged, G; Moriyama, K; Suda, N | 1 |
| Fukuda, D; Hirata, Y; Kurobe, H; Maeda, N; Masuzaki, H; Sakaue, H; Sata, M; Sato, H; Shimabukuro, M; Shimomura, I; Shiota, A; Soeki, T; Uematsu, E | 1 |
| Alter, ML; Henze, A; Hocher, B; Klein, T; Krause-Relle, K; Ott, IM; Raila, J; Sharkovska, Y; Tsuprykov, O; von Websky, K | 1 |
| Boor, P; Cohen, CD; Denecke, B; Eitner, F; Floege, J; Gan, L; Konieczny, A; Kunter, U; Neusser, MA; Ostendorf, T; Scholl, T; van Roeyen, CR; Villa, L | 1 |
| Fujiwara, M; Irie, K; Iwasaki, K; Katsurabayashi, S; Kubota, K; Mishima, K; Nishimura, R; Onimura, R; Shindo, T; Takasaki, K; Uchida, K; Uchida, N | 1 |
| Demir, M; Dienes, HP; Goeser, T; Hunt, H; Mende, S; Nierhoff, D; Odenthal, M; Pryymachuck, G; Quasdorff, M; Schulte, S; Steffen, HM; Strack, I; Töx, U | 1 |
| Engeli, S; Gorzelniak, K; Janke, J; Luft, FC; Sharma, AM | 1 |
| Doggrell, SA | 1 |
| Corry, DB; Tuck, ML | 1 |
| Inoue, M; Ishida, S; Koto, T; Kubota, Y; Nagai, N; Noda, K; Oike, Y; Ozawa, Y; Shinoda, H; Shinoda, K; Suda, T; Tsubota, K; Urano, T; Yamashiro, K | 1 |
| Bley, S; Drexler, H; Grote, K; Grothusen, C; Luchtefeld, M; Schieffer, B; Selle, T; Tietge, UJ | 1 |
| Kira, S; Kobayashi, M; Maeshima, Y; Makino, H; Masuoka, N; Sugiyama, H; Sunami, R; Wang, DH; Yamasaki, Y | 1 |
| Cibulskyte, D; Frøkiaer, J; Hansen, HE; Hørlyck, A; Madsen, M; Marcussen, N; Mortensen, J; Pedersen, M | 1 |
| Inoue, M; Ishida, S; Kurihara, T; Nagai, N; Oike, Y; Okano, H; Ozawa, Y; Shinoda, K; Tsubota, K | 1 |
| Itoh, Y; Mori, Y; Tajima, N | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Chachin, M; Hayashi, N; Hayashi, T; Horie, Y; Konomi, A; Matsumaru, T; Ohmura, T; Seidler, R; Sumida, T; Tsunenari, I | 1 |
| Kariv, N; Nachman, R; Rosenthal, T; Younis, F; Zangen, S | 1 |
| Dai, Q; Sun, B; Xu, M; Yao, M | 1 |
| Ishimitsu, T; Matsuoka, H; Ono, H; Ono, Y; Takahashi, T | 1 |
| Bedette, D; Fontes, MA; Santos, RA | 1 |
| Jin, D; Kimura, M; Kirimura, K; Miyazaki, M; Sakonjo, H; Takai, S; Tanaka, K | 1 |
| Ito, Y; Oyunzul, L; Takeuchi, C; Yamada, S | 1 |
| Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K | 1 |
| Cai, YM; Gu, HB; Hao, YH; He, JG; Hu, XS; Liao, XX; Ma, H; Tian, F; Wang, LJ; Zhang, WW; Zhou, QL; Zou, HM | 1 |
| Fukushima, H; Hirata, H; Kobayashi, N; Machida, Y; Mamada, Y; Matsuoka, H; Nomura, M; Ohno, T; Shinoda, M; Suzuki, N; Yoshida, K | 1 |
3 review(s) available for telmisartan and Disease Models, Animal
| Article | Year |
|---|---|
Pathogenic and Therapeutic Significance of Angiotensin II Type I Receptor in Abdominal Aortic Aneurysms.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Aneurysm, Abdominal; Aortic Rupture; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Humans; Receptor, Angiotensin, Type 1; Telmisartan; Valsartan | 2018 |
Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atherosclerosis; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Culture Techniques; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Gene Knockout Techniques; Glucose; Humans; Hypertension; Kidney; Lipid Metabolism; Metabolic Diseases; Oxadiazoles; Renin-Angiotensin System; Stroke; Telmisartan | 2016 |
Telmisartan - killing two birds with one stone.
Topics: 3T3-L1 Cells; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypertension; Insulin Resistance; Irbesartan; Mice; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Tetrazoles | 2004 |
147 other study(ies) available for telmisartan and Disease Models, Animal
| Article | Year |
|---|---|
6-Amino[1,2,5]oxadiazolo[3,4-
Topics: Alanine Transaminase; Aniline Compounds; Animals; Cell Line; Diet, High-Fat; Disease Models, Animal; Half-Life; Liver; Mice; Mitochondria; Myoblasts; Non-alcoholic Fatty Liver Disease; Oxygen Consumption; Pyrazines; Rats; Structure-Activity Relationship; Triglycerides; Uncoupling Protein 1 | 2020 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Evaluation of nootropic activity of telmisartan and metformin on diazepam-induced cognitive dysfunction in mice through AMPK pathway and amelioration of hippocampal morphological alterations.
Topics: AMP-Activated Protein Kinases; Animals; Behavior, Animal; Caspase 3; Cell Death; Cognitive Dysfunction; Diazepam; Disease Models, Animal; Hippocampus; Maze Learning; Metformin; Mice; Neuroprotective Agents; NF-kappa B; Nootropic Agents; Piracetam; Signal Transduction; Telmisartan; Tumor Necrosis Factor-alpha | 2021 |
The relationship of telmisartan with sclerostin in the osteoporosis model induced by ovariectomy in rats.
Topics: Adaptor Proteins, Signal Transducing; Alkaline Phosphatase; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Disease Models, Animal; Estrogens; Female; Genetic Markers; Osteocalcin; Osteogenesis; Osteopontin; Osteoporosis; Ovariectomy; Rats, Sprague-Dawley; Receptors, Angiotensin; RNA, Messenger; Tartrate-Resistant Acid Phosphatase; Telmisartan | 2021 |
Effect of telmisartan on an experimental model of periodontitis in mice.
Topics: Alveolar Bone Loss; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred BALB C; Models, Theoretical; Periodontitis; Porphyromonas gingivalis; Telmisartan; X-Ray Microtomography | 2023 |
Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Firmicutes; Fructose; Gastrointestinal Microbiome; Glucans; Humans; Isoleucine; Leucine; Metabolome; Mice; Non-alcoholic Fatty Liver Disease; Ornithine; RNA, Ribosomal, 16S; Spermidine; Succinic Acid; Telmisartan; Tryptophan; Water | 2022 |
Protective Effects of Lovastatin in a Population-Based ALS Study and Mouse Model.
Topics: Aged; Amyotrophic Lateral Sclerosis; Animals; Case-Control Studies; Disease Models, Animal; Humans; Medicare; Mice; Mice, Transgenic; Motor Neuron Disease; Spinal Cord; Sulfasalazine; Superoxide Dismutase; Superoxide Dismutase-1; Telmisartan; United States | 2023 |
Telmisartan Alleviates Alzheimer's Disease-Related Neuropathologies and Cognitive Impairments.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory Agents; Cognitive Dysfunction; Disease Models, Animal; Mice; Mice, Transgenic; Neuroinflammatory Diseases; Telmisartan | 2023 |
Stachydrine hydrochloride alleviates pressure overload-induced heart failure and calcium mishandling on mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Arterial Pressure; Calcium Signaling; Calcium-Binding Proteins; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Heart Failure; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphorylation; Proline; Rats; Rats, Sprague-Dawley; Ryanodine Receptor Calcium Release Channel; Sarcomeres; Sarcoplasmic Reticulum; Telmisartan; Ventricular Function, Left | 2020 |
Telmisartan Inhibits Nitric Oxide Production and Vessel Relaxation via Protein Phosphatase 2A-mediated Endothelial NO Synthase-Ser
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Cattle; Disease Models, Animal; Endothelium, Vascular; Hyperglycemia; Male; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Nitrites; Phosphorylation; Protein Phosphatase 2; Protein Phosphatase 2C; Rats; Serine; Telmisartan | 2019 |
Telmisartan/17β-estradiol mitigated cognitive deficit in an ovariectomized rat model of Alzheimer's disease: Modulation of ACE1/ACE2 and AT1/AT2 ratio.
Topics: Alzheimer Disease; Animals; Blotting, Western; Cognitive Dysfunction; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Estradiol; Female; Hippocampus; Maze Learning; Nootropic Agents; Ovariectomy; Rats; Rats, Wistar; Renin-Angiotensin System; Telmisartan | 2020 |
Telmisartan alone or in combination with etanercept improves anemia associated with rheumatoid arthritis in rats: a possible role of anti-inflammatory and reno-protective effects.
Topics: Anemia; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Creatinine; Cytokines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Etanercept; Freund's Adjuvant; Iron; Rats, Wistar; Telmisartan; Urea | 2020 |
Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Disease Models, Animal; Endothelial Cells; Heart Failure; Leukocyte Rolling; Macrophages; Male; Mice, Inbred C57BL; Monocytes; Muramidase; Myeloid Cells; Myocardial Infarction; NADPH Oxidase 2; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Vasculitis | 2021 |
Study on the Formation of Antihypertensive Twin Drugs by Caffeic Acid and Ferulic Acid with Telmisartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Caffeic Acids; Coumaric Acids; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Molecular Structure; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Structure-Activity Relationship; Telmisartan | 2020 |
Telmisartan Reduces Axon Degeneration in Mice With Experimental Glaucoma.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Axons; Disease Models, Animal; Female; Glaucoma; Male; Mice; Mice, Inbred C57BL; Retinal Ganglion Cells; Telmisartan | 2020 |
Telmisartan Exacerbates Cisplatin-Induced Nephrotoxicity in a Mouse Model.
Topics: Acute Kidney Injury; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blood Pressure; Blood Urea Nitrogen; Calcium Channel Blockers; Cisplatin; Creatinine; Disease Models, Animal; Drug Synergism; Fibrosis; Humans; Injections, Intraperitoneal; Kidney; Male; Mice; Neoplasms; Severity of Illness Index; Telmisartan | 2020 |
PPARγ Activation-Mediated Egr-1 Inhibition Benefits Against Brain Injury in an Experimental Ischaemic Stroke Model.
Topics: Animals; Anti-Inflammatory Agents; Brain; Claudin-5; Disease Models, Animal; Early Growth Response Protein 1; Infarction, Middle Cerebral Artery; Male; PPAR gamma; Rats, Sprague-Dawley; Signal Transduction; Telmisartan | 2020 |
Obesity and metabolic syndrome related macrophage promotes PD-L1 expression in TNBC through IL6/JAK/STAT pathway and can be reversed by telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; B7-H1 Antigen; Biomarkers, Tumor; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Metabolic Syndrome; Obesity; Rats; Rats, Wistar; Telmisartan; Triple Negative Breast Neoplasms | 2020 |
Zinc complexation improves angiotensin II receptor type 1 blockade and
Topics: Animals; Antihypertensive Agents; Arteries; Calcium; Cell Line; Coordination Complexes; Disease Models, Animal; Humans; Hypertension; Male; Protein Binding; Rats, Wistar; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Telmisartan; Transfection; Zinc | 2021 |
Telmisartan prevents high-fat diet-induced neurovascular impairments and reduces anxiety-like behavior.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anxiety; Diet, High-Fat; Disease Models, Animal; Male; Mice; Obesity; Telmisartan | 2021 |
Countering adipose tissue dysfunction could underlie the superiority of telmisartan in the treatment of obesity-related hypertension.
Topics: Adiposity; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Disease Models, Animal; Hypertension; Intra-Abdominal Fat; Kidney; Male; Obesity; Rats, Wistar; Telmisartan | 2021 |
Cardioprotective effects of azilsartan compared with that of telmisartan on an in vivo model of myocardial ischemia-reperfusion injury.
Topics: Animals; Benzimidazoles; Cardiotonic Agents; Disease Models, Animal; Male; MAP Kinase Signaling System; Myocardial Reperfusion Injury; Myocardium; Oxadiazoles; Rats; Rats, Wistar; Telmisartan | 2021 |
Telmisartan induces a specific gut microbiota signature which may mediate its antiobesity effect.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Bacteria; Diet; Disease Models, Animal; Dysbiosis; Fecal Microbiota Transplantation; Feces; Gastrointestinal Microbiome; Mice; Obesity; Rats; Rats, Sprague-Dawley; Telmisartan; Weight Gain | 2021 |
Telmisartan Attenuates the Growth of Epithelium-like Cells and Glomerular Injury in Spontaneously Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Epithelium; Humans; Hypertension; Hypertension, Renal; Kidney; Nephritis; Rats; Rats, Inbred SHR; Telmisartan | 2021 |
Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cardio-Renal Syndrome; Diastole; Disease Models, Animal; Echocardiography; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Male; Natriuretic Peptide, Brain; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Stroke Volume; Telmisartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice.
Topics: Administration, Intranasal; Alzheimer Disease; Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cell Polarity; Cerebral Cortex; Disease Models, Animal; Encephalitis; Female; Gliosis; Humans; Male; Mice; Mice, Transgenic; Microglia; Spatial Processing; Telmisartan | 2017 |
Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Benzimidazoles; Benzoates; Dilatation, Pathologic; Disease Models, Animal; Gene Expression Regulation; Genetic Predisposition to Disease; Mice, Inbred C57BL; Mice, Knockout; Pancreatic Elastase; Phenotype; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Time Factors; Transcriptome | 2018 |
Combination therapy with telmisartan and parecoxib induces regression of endometriotic lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Caspase 3; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Endometriosis; Female; Isoxazoles; Matrix Metalloproteinase 9; Mice, Inbred C57BL; PPAR gamma; Proto-Oncogene Proteins c-akt; Telmisartan; Ultrasonography | 2017 |
Enhanced Mitochondrial Transient Receptor Potential Channel, Canonical Type 3-Mediated Calcium Handling in the Vasculature From Hypertensive Rats.
Topics: Adenosine Triphosphate; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium; Calcium Signaling; Cells, Cultured; Disease Models, Animal; Energy Metabolism; Hypertension; Male; Mice, Knockout; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidation-Reduction; Rats, Inbred SHR; Rats, Inbred WKY; Reactive Oxygen Species; Telmisartan; Time Factors; TRPC Cation Channels; Up-Regulation; Vasoconstriction | 2017 |
Potential of telmisartan in the treatment of benign prostatic hyperplasia.
Topics: Administration, Oral; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Random Allocation; Rats; Rats, Wistar; Telmisartan; Testosterone | 2017 |
Effect of Telmisartan on Preventing Learning and Memory Deficits Via Peroxisome Proliferator-Activated Receptor-γ in Vascular Dementia Spontaneously Hypertensive Rats.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Benzimidazoles; Benzoates; Choline O-Acetyltransferase; Dementia, Vascular; Disease Models, Animal; Drug Partial Agonism; GPI-Linked Proteins; Hippocampus; Infarction, Middle Cerebral Artery; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Maze Learning; Memory; Nootropic Agents; PPAR gamma; Rats, Inbred SHR; Signal Transduction; Synaptophysin; Telmisartan | 2018 |
Comparing the antifibrotic effect on the liver of Telmisartan and Pentoxifylline, in a Wistar rat experimental model.
Topics: Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Fibrosis; Liver; Models, Theoretical; Pentoxifylline; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Telmisartan | 2017 |
Telmisartan protects chronic intermittent hypoxic mice via modulating cardiac renin-angiotensin system activity.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Chronic Disease; Disease Models, Animal; Endothelial Cells; Heart Diseases; Hypoxia; Male; Mice, Inbred C57BL; Mitochondria, Heart; Myocardium; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Telmisartan | 2018 |
Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.
Topics: alpha-Synuclein; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Calcium-Binding Proteins; Cell Death; Cytokines; Dependovirus; Disease Models, Animal; Dopaminergic Neurons; Encephalitis; Glial Fibrillary Acidic Protein; Green Fluorescent Proteins; Humans; Male; Microfilament Proteins; Microscopy, Confocal; Mutation; Rats; Rats, Sprague-Dawley; Synapsins; Telmisartan; Tetrazoles; Transduction, Genetic; Tyrosine 3-Monooxygenase | 2018 |
Telmisartan Ameliorates Astroglial and Dopaminergic Functions in a Mouse Model of Chronic Parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Angiotensin II Type 1 Receptor Blockers; Animals; Astrocytes; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine; Gene Expression Regulation; Glutathione; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Nitric Oxide; Parkinsonian Disorders; Psychomotor Disorders; Substantia Nigra; Telmisartan; Walking | 2018 |
Telmisartan attenuates kidney apoptosis and autophagy-related protein expression levels in an intermittent hypoxia mouse model.
Topics: Angiotensin II; Animals; Apoptosis; Autophagy-Related Proteins; Blood Urea Nitrogen; Body Weight; Creatinine; Disease Models, Animal; Hypoxia; In Situ Nick-End Labeling; Kidney; Male; Mice; Mice, Inbred C57BL; Telmisartan | 2019 |
Modulation of inducible nitric oxide synthase pathway by eugenol and telmisartan in carbon tetrachloride-induced liver injury in rats.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Drug Therapy, Combination; Eugenol; Glutathione; Interleukin-6; Liver Cirrhosis; Male; Malondialdehyde; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Telmisartan; Tumor Necrosis Factor-alpha | 2019 |
Telmisartan attenuates diabetic nephropathy progression by inhibiting the dimerization of angiotensin type-1 receptor and adiponectin receptor-1.
Topics: Animals; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dimerization; Disease Models, Animal; Fibrosis; Kidney; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, Adiponectin; RNA, Small Interfering; Streptozocin; Telmisartan | 2019 |
Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Disease Models, Animal; Drug Design; Female; Gene Expression Regulation; Half-Life; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Polymers; Prodrugs; Rats; Rats, Sprague-Dawley; Telmisartan | 2018 |
Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Disease Models, Animal; Hypertension; Insulin Resistance; Mice; Mice, Knockout; PPAR gamma; Telmisartan | 2013 |
Abnormal amounts of intracellular calcium regulatory proteins in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome and cardiac dysfunction.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Body Weight; Calcium; Calcium-Binding Proteins; Cholesterol; Coronary Circulation; Diastole; Disease Models, Animal; Heart Function Tests; Insulin; Male; Metabolic Syndrome; Myocytes, Cardiac; Phosphorylation; Rats; Rats, Inbred Strains; Sarcoplasmic Reticulum; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Serine; Telmisartan; Triglycerides; Ventricular Dysfunction; Ventricular Function, Left | 2013 |
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.
Topics: Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cyclooxygenase 2 Inhibitors; Desoxycorticosterone Acetate; Disease Models, Animal; Etoricoxib; Hypertension; Mineralocorticoids; Pyridines; Ramipril; Rats; Rats, Sprague-Dawley; Sodium Chloride; Sulfones; Telmisartan | 2013 |
Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.
Topics: Aminoacyltransferases; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cell Line, Tumor; Chemokine CCL2; Disease Models, Animal; Enzyme Inhibitors; Fatty Liver; Hepatitis; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Monocytic, Acute; Macrophages; Mice; Mice, Inbred C57BL; Monocytes; Non-alcoholic Fatty Liver Disease; Telmisartan | 2013 |
Administration of telmisartan reduced systolic blood pressure and oxidative stress probably through the activation of PI3K/Akt/eNOS pathway and NO release in spontaneously hypertensive rats.
Topics: AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Enzyme Activation; Hypertension; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Superoxide Dismutase; Telmisartan; Time Factors | 2013 |
Telmisartan inhibits AGE-induced podocyte damage and detachment.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blotting, Western; Cell Adhesion; Diabetic Nephropathies; Disease Models, Animal; DNA Damage; Glycation End Products, Advanced; L-Lactate Dehydrogenase; Mice; Podocytes; Telmisartan | 2013 |
Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anthelmintics; Benzimidazoles; Benzoates; Disease Models, Animal; Drug Therapy, Combination; Liver; Liver Cirrhosis; Male; Mice; PPAR gamma; Praziquantel; Schistosomiasis mansoni; Telmisartan; Treatment Outcome | 2013 |
Angiotensin II receptor type 1--a novel target for preventing neonatal meningitis in mice by Escherichia coli K1.
Topics: Animals; Animals, Newborn; Antigens, Bacterial; Bacterial Capsules; Benzimidazoles; Benzoates; Cell Line; Chemoprevention; Disease Models, Animal; Endothelial Cells; Escherichia coli; Humans; Meningitis, Escherichia coli; Mice; Mice, Inbred C57BL; Polysaccharides, Bacterial; Receptor, Angiotensin, Type 1; Telmisartan | 2014 |
Effect of telmisartan on levels of IL-1, TNF-α, down-regulated COX-2, MMP-2, MMP-9 and RANKL/RANK in an experimental periodontitis model.
Topics: Alveolar Bone Loss; Animals; Anti-Inflammatory Agents; Antioxidants; Benzimidazoles; Benzoates; Cyclooxygenase 2; Disease Models, Animal; Down-Regulation; Glutathione; Interleukin-10; Interleukin-1beta; Male; Malondialdehyde; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Osteoprotegerin; Oxidative Stress; Periodontitis; Peroxidase; Random Allocation; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Telmisartan; Tumor Necrosis Factor-alpha | 2013 |
Telmisartan attenuates monocrotaline-induced pulmonary artery endothelial dysfunction through a PPAR gamma-dependent PI3K/Akt/eNOS pathway.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Endothelium, Vascular; Hypertension, Pulmonary; Male; Monocrotaline; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinases; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; Pulmonary Artery; Rats; Rats, Sprague-Dawley; Signal Transduction; Telmisartan | 2014 |
Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Drug Partial Agonism; Endothelium, Vascular; Hypertension; Losartan; Male; Nitric Oxide Synthase Type III; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Vasodilation | 2013 |
Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cell Proliferation; Cysts; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Hepatocytes; Humans; Kidney Function Tests; Liver; Liver Diseases; Liver Function Tests; Male; Organ Size; Polycystic Kidney, Autosomal Recessive; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta | 2013 |
Long-term effect of telmisartan on Alzheimer's amyloid genesis in SHR-SR after tMCAO.
Topics: Age Factors; Amyloid beta-Peptides; Analysis of Variance; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Brain; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Functional Laterality; Hippocampus; Infarction, Middle Cerebral Artery; Longitudinal Studies; Male; Plaque, Amyloid; Rats; Rats, Inbred SHR; Telmisartan; Triglycerides | 2015 |
Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Down-Regulation; Endometriosis; Female; Gene Expression Profiling; Mice; Neovascularization, Pathologic; Peritoneal Diseases; Pioglitazone; PPAR gamma; Telmisartan; Thiazolidinediones; Up-Regulation | 2014 |
Telmisartan treatment ameliorates memory deficits in streptozotocin-induced diabetic mice via attenuating cerebral amyloidosis.
Topics: Administration, Oral; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Angiotensin II Type 1 Receptor Blockers; Animals; Aspartic Acid Endopeptidases; Benzimidazoles; Benzoates; Cerebral Amyloid Angiopathy; Cerebral Cortex; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Disease Models, Animal; Hippocampus; Male; Memory Disorders; Mice; Mice, Inbred ICR; Peptide Fragments; Receptor for Advanced Glycation End Products; Streptozocin; Telmisartan; Transcription Factor RelA; Treatment Outcome | 2014 |
Telmisartan improves survival and ventricular function in SHR rats with extensive cardiovascular damage induced by dietary salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Body Weight; Diastole; Disease Models, Animal; Hypertension; Hypertrophy, Left Ventricular; Male; Random Allocation; Rats, Inbred SHR; Sodium, Dietary; Telmisartan; Ventricular Dysfunction | 2014 |
Telmisartan attenuates colon inflammation, oxidative perturbations and apoptosis in a rat model of experimental inflammatory bowel disease.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Antioxidants; Apoptosis; Benzimidazoles; Benzoates; Colitis; Colon; Disease Models, Animal; Glutathione; Glutathione Peroxidase; Immunohistochemistry; Inflammation; Inflammatory Bowel Diseases; Lipid Peroxidation; Male; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidative Stress; Rats; Rats, Wistar; RNA, Messenger; Superoxide Dismutase; Telmisartan; Trinitrobenzenesulfonic Acid | 2014 |
Telmisartan exerts sustained blood pressure control and reduces blood pressure variability in metabolic syndrome by inhibiting sympathetic activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; Baroreflex; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Disease Models, Animal; Equipment Design; Hypertension; Metabolic Syndrome; Rats; Rats, Inbred SHR; Telemetry; Telmisartan | 2014 |
Investigation of the effect of telmisartan on experimentally induced peripheral nerve injury in rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Caspase 3; Disease Models, Animal; Gene Expression Regulation; Interleukin-1beta; Locomotion; Male; Rats; Rats, Wistar; RNA, Messenger; Sciatic Neuropathy; Telmisartan; Time Factors | 2015 |
Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.
Topics: Animals; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Guanylate Cyclase; Male; Mesenteric Arteries; Metabolic Syndrome; Nitric Oxide; Nitroprusside; Oligopeptides; Oxidative Stress; Rats; Rats, Inbred WKY; Receptor, PAR-2; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan; Thiobarbituric Acid Reactive Substances; Vasodilation | 2014 |
Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model.
Topics: Amine Oxidase (Copper-Containing); Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Enzyme Inhibitors; Fibrosis; Kidney; Kidney Diseases; Mice, Inbred C57BL; Semicarbazides; Telmisartan; Ureteral Obstruction | 2014 |
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Disease Progression; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Male; NFATC Transcription Factors; Rats; Rats, Inbred SHR; Signal Transduction; Telmisartan; TRPC Cation Channels | 2015 |
Telmisartan attenuates myocardial apoptosis induced by chronic intermittent hypoxia in rats: modulation of nitric oxide metabolism and inflammatory mediators.
Topics: Animals; Apoptosis; Benzimidazoles; Benzoates; C-Reactive Protein; Disease Models, Animal; Hypoxia; Inflammation Mediators; Interleukin-6; Lipid Peroxidation; Male; Myocardium; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sleep Apnea, Obstructive; Telmisartan | 2015 |
Chronic intermittent hypoxia-induced neuronal apoptosis in the hippocampus is attenuated by telmisartan through suppression of iNOS/NO and inhibition of lipid peroxidation and inflammatory responses.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; C-Reactive Protein; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Hippocampus; Hypoxia; In Situ Nick-End Labeling; Inflammation; Interleukin-6; Leukocyte Common Antigens; Lipid Peroxidation; Male; Nitric Oxide; Nitric Oxide Synthase Type II; Rats; Rats, Sprague-Dawley; Telmisartan | 2015 |
Neurovascular protection by telmisartan via reducing neuroinflammation in stroke-resistant spontaneously hypertensive rat brain after ischemic stroke.
Topics: Acetylglucosamine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Carrier Proteins; Cerebral Cortex; Collagen Type IV; Disease Models, Animal; Encephalitis; Glial Fibrillary Acidic Protein; Hypertension; Infarction, Middle Cerebral Artery; Inflammasomes; Male; Matrix Metalloproteinase 9; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Rats, Inbred SHR; Telmisartan; Time Factors | 2015 |
Telmisartan promotes potential glucose homeostasis in stroke-resistant spontaneously hypertensive rats via peroxisome proliferator-activated receptor γ activation.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Glucose; Homeostasis; Male; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Wistar; Receptor, Angiotensin, Type 1; Stroke; Telmisartan | 2015 |
Protective effect of telmisartan on neurovascular unit and inflammasome in stroke-resistant spontaneously hypertensive rats.
Topics: Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Carrier Proteins; Cerebral Cortex; Collagen; Disease Models, Animal; Dose-Response Relationship, Drug; Glial Fibrillary Acidic Protein; Hypertension; Immunohistochemistry; Inflammasomes; Male; Matrix Metalloproteinase 9; Neurovascular Coupling; NLR Family, Pyrin Domain-Containing 3 Protein; Rats, Inbred SHR; Rats, Wistar; Telmisartan | 2015 |
Telmisartan treatment targets inflammatory cytokines to suppress the pathogenesis of acute colitis induced by dextran sulphate sodium.
Topics: Acute Disease; Animals; Benzimidazoles; Benzoates; Caspase 3; Caspase 7; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Female; Mice; Proto-Oncogene Proteins c-bcl-2; Telmisartan | 2015 |
Telmisartan decreases inflammation by modulating TNF-α, IL-10, and RANK/RANKL in a rat model of ulcerative colitis.
Topics: Animals; Benzimidazoles; Benzoates; Colitis, Ulcerative; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Inflammation; Interleukin-10; RANK Ligand; Rats; Rats, Wistar; Receptor Activator of Nuclear Factor-kappa B; Telmisartan; Tumor Necrosis Factor-alpha | 2015 |
[Effects of telmisartan on resistin expression in a rat model of nonalcoholic steatohepatitis and insulin resistance].
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Benzimidazoles; Benzoates; Cholesterol; Diet, High-Fat; Disease Models, Animal; Insulin; Insulin Resistance; Male; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Resistin; Telmisartan; Triglycerides | 2015 |
Telmisartan reduces atrial arrhythmia susceptibility through the regulation of RAS-ERK and PI3K-Akt-eNOS pathways in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Apoptosis; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibrosis; Heart Rate; Hypertension; Male; Myocytes, Cardiac; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; ras Proteins; Rats, Inbred SHR; Rats, Inbred WKY; Signal Transduction; Telmisartan; Time Factors; Valsartan | 2015 |
Development of telmisartan in the therapy of spinal cord injury: pre-clinical study in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Benzoates; Disease Models, Animal; HMGB1 Protein; Male; Motor Activity; Nociception; PPAR gamma; Rats, Wistar; Receptor for Advanced Glycation End Products; Spinal Cord; Spinal Cord Injuries; Telmisartan; Time Factors; Up-Regulation | 2015 |
The pharmacokinetic-pharmacodynamic model of telmisartan and hydrochlorothiazide on blood pressure and plasma potassium after long-term administration in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Determination; Disease Models, Animal; Drug Therapy, Combination; Hydrochlorothiazide; Hypertension; Male; Potassium; Rats; Rats, Inbred SHR; Telmisartan | 2015 |
Combination of Telmisartan and Linagliptin Preserves Pancreatic Islet Cell Function and Morphology in db/db Mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blotting, Western; Cell Line, Tumor; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Female; Glucose Tolerance Test; Humans; Immunohistochemistry; Islets of Langerhans; Linagliptin; Mice; Mice, Inbred C57BL; Oxidative Stress; Pancreas; PPAR gamma; Reactive Oxygen Species; Telmisartan | 2016 |
Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Contrast Media; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelial Progenitor Cells; Fibrosis; Flow Cytometry; Gadolinium DTPA; Magnetic Resonance Imaging; Manganese; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Electron, Transmission; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Predictive Value of Tests; Recovery of Function; Stroke Volume; Telmisartan; Time Factors; Tissue Survival; Ventricular Function, Left | 2016 |
Inhibition of endoplasmic reticulum stress-activated IRE1α-TRAF2-caspase-12 apoptotic pathway is involved in the neuroprotective effects of telmisartan in the rotenone rat model of Parkinson's disease.
Topics: Animals; Apoptosis; Benzimidazoles; Benzoates; Caspase 12; Catalepsy; Disease Models, Animal; Dopamine; Endoplasmic Reticulum Stress; Endoribonucleases; Enzyme Activation; Male; Multienzyme Complexes; Neostriatum; Neuroprotective Agents; Parkinson Disease; Pars Compacta; PPAR delta; PPAR-beta; Protein Serine-Threonine Kinases; Rats; Rotenone; Signal Transduction; Telmisartan; TNF Receptor-Associated Factor 2 | 2016 |
Combination therapy with renin-angiotensin-aldosterone system inhibitor telmisartan and serine protease inhibitor camostat mesilate provides further renoprotection in a rat chronic kidney disease model.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Creatinine; Disease Models, Animal; Drug Therapy, Combination; Esters; Fibrosis; Gabexate; Guanidines; Kidney; Male; Oxidative Stress; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Serine Proteinase Inhibitors; Telmisartan | 2016 |
Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Blotting, Western; Cell Movement; Cytokines; Dendritic Cells; Diabetes Mellitus, Experimental; Diet, High-Fat; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Glycerophosphates; Glycerylphosphorylcholine; Hepatic Stellate Cells; Humans; Inflammation; Kupffer Cells; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Monocytes; Non-alcoholic Fatty Liver Disease; Phospholipids; Pyridinium Compounds; Real-Time Polymerase Chain Reaction; Telmisartan; Toll-Like Receptor 2; Toll-Like Receptor 4; Triglycerides | 2016 |
Telmisartan ameliorates oxidative stress and subarachnoid haemorrhage-induced cerebral vasospasm.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Gas Analysis; Brain Stem; Carrier Proteins; Cell Cycle Proteins; Disease Models, Animal; Male; Malondialdehyde; Oxidative Stress; Rabbits; Reactive Oxygen Species; RNA, Messenger; Statistics, Nonparametric; Subarachnoid Hemorrhage; Telmisartan; Thioredoxins; Tumor Necrosis Factor-alpha; Vasospasm, Intracranial | 2016 |
The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Blood Pressure; Chromatography, Liquid; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Fibrosis; Kidney; Linagliptin; Male; Mass Spectrometry; Nephrectomy; Rats, Inbred F344; Rats, Sprague-Dawley; Rats, Transgenic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Signal Transduction; Telmisartan; Time Factors | 2016 |
Combination of telmisartan with sildenafil ameliorate progression of diabetic nephropathy in streptozotocin-induced diabetic model.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Urea Nitrogen; Body Weight; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Glycation End Products, Advanced; Interleukin-1beta; Kidney; Nitric Oxide; Proteinuria; Rats; Sildenafil Citrate; Streptozocin; Superoxide Dismutase; Telmisartan; Transforming Growth Factor beta1 | 2016 |
Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release From Perirenal Adipose Tissue.
Topics: Adipogenesis; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Intra-Abdominal Fat; Kidney Diseases; Leptin; Male; Metabolic Syndrome; Protective Agents; Rats; Rats, Wistar; Telmisartan | 2016 |
Type-1 angiotensin receptor signaling in central nervous system myeloid cells is pathogenic during fatal alphavirus encephalitis in mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; ATPases Associated with Diverse Cellular Activities; Benzimidazoles; Benzoates; Central Nervous System; CX3C Chemokine Receptor 1; Disease Models, Animal; DNA Helicases; Encephalomyelitis, Equine; Gene Expression Regulation; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Neurons; Oxygen Consumption; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, Chemokine; Receptors, Immunologic; Signal Transduction; Telmisartan | 2016 |
Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apoptosis; Benzimidazoles; Benzoates; Blood Pressure; Cathepsin D; Disease Models, Animal; Dose-Response Relationship, Drug; Hydralazine; Inflammation; Male; Matrix Metalloproteinase 3; NF-kappa B; Protein Denaturation; Rats; Rats, Inbred BN; Telmisartan; Tumor Necrosis Factor-alpha | 2008 |
Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoimmune Diseases; Benzimidazoles; Benzoates; Cell Adhesion; Chemokine CCL2; Cytokines; Disease Models, Animal; Down-Regulation; Eye Proteins; Female; Flow Cytometry; Hypersensitivity, Delayed; Intercellular Adhesion Molecule-1; Lymph Nodes; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Retinitis; Retinol-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes; Telmisartan; Uveitis | 2009 |
Protective effects of telmisartan on ischemia/reperfusion injury of rat ovary: biochemical and histopathologic evaluation.
Topics: Animals; Antioxidants; Benzimidazoles; Benzoates; Disease Models, Animal; Female; Nitric Oxide Synthase Type II; Ovary; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Reperfusion Injury; Superoxide Dismutase; Telmisartan | 2010 |
Losartan reduces liver expression of plasminogen activator inhibitor-1 (PAI-1) in a high fat-induced rat nonalcoholic fatty liver disease model.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dietary Fats; Disease Models, Animal; Fatty Liver; Liver; Losartan; Male; Phosphoenolpyruvate Carboxykinase (GTP); Plasminogen Activator Inhibitor 1; PPAR alpha; Rats; Rats, Sprague-Dawley; Telmisartan; Triglycerides | 2009 |
Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Cell Line; Cell Size; Chemokine CCL2; Choline Deficiency; Collagen Type I; Disease Models, Animal; Disease Progression; Drinking; Eating; Fatty Liver; Intra-Abdominal Fat; Liver; Liver Cirrhosis; Macrophages; Male; Methionine; Mice; Mice, Inbred C57BL; Organ Size; Oxidative Stress; Receptors, CCR2; RNA, Messenger; Telmisartan; Transforming Growth Factor beta1; Triglycerides | 2009 |
Angiotensin II type 1 receptor blocker telmisartan reduces cerebral infarct volume and peri-infarct cytosolic phospholipase A(2) level in experimental stroke.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Brain; Brain Infarction; Brain Ischemia; Cytoprotection; Cytosol; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Immunohistochemistry; Infarction, Middle Cerebral Artery; Male; Motor Cortex; Neurons; Phospholipases A2; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Stroke; Telmisartan | 2009 |
Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Cerebellum; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Injections, Intraventricular; Male; Maze Learning; Mice; Mice, Inbred Strains; Nitric Oxide Synthase Type II; PPAR gamma; Regional Blood Flow; Telmisartan; Tumor Necrosis Factor-alpha | 2009 |
Myocardial salvaging effect of telmisartan in experimental model of myocardial infarction.
Topics: Animals; Benzimidazoles; Benzoates; Biomarkers; Body Weight; Cardiotonic Agents; Catalase; Disease Models, Animal; Heart; Isoproterenol; L-Lactate Dehydrogenase; Lipid Peroxidation; Male; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Superoxide Dismutase; Telmisartan | 2009 |
An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Disease Models, Animal; Dose-Response Relationship, Drug; Energy Metabolism; Female; Glucose Tolerance Test; Insulin; Insulin Resistance; Lipodystrophy; Liver; Mice; Mice, Transgenic; Organ Size; PPAR gamma; Telmisartan; Transcription Factors; Triglycerides | 2009 |
The effects of telmisartan on mechanical responses of left ventricular papillary muscle in rats with streptozotocin-induced diabetes mellitus.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; Disease Models, Animal; Heart Ventricles; Humans; Male; Myocardial Contraction; Papillary Muscles; Rats; Rats, Wistar; Streptozocin; Telmisartan | 2010 |
HIVAN phenotype: consequence of epithelial mesenchymal transdifferentiation.
Topics: Actins; AIDS-Associated Nephropathy; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cadherins; Calcium-Binding Proteins; Cell Proliferation; Cell Transdifferentiation; Disease Models, Animal; Epithelial Cells; Fibroblasts; HIV-1; Infusions, Subcutaneous; Kidney Glomerulus; Kidney Tubules; Macrophages; Mice; Mice, Transgenic; Phenotype; Podocytes; Proliferating Cell Nuclear Antigen; Receptor, Angiotensin, Type 1; RNA, Messenger; S100 Calcium-Binding Protein A4; S100 Proteins; T-Lymphocytes; Telmisartan | 2010 |
Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Benzimidazoles; Benzoates; Blood Pressure; Blood Urea Nitrogen; Caspase 3; Catalase; Creatinine; Disease Models, Animal; Glutathione; Homocysteine; Kidney; Kidney Diseases; Male; Malondialdehyde; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Superoxide Dismutase; Telmisartan; Tumor Necrosis Factor-alpha | 2010 |
Modulation of PPAR-gamma by telmisartan protects the heart against myocardial infarction in experimental diabetes.
Topics: Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Diabetes Mellitus, Experimental; Disease Models, Animal; Heart; Male; Myocardial Infarction; Myocardium; PPAR gamma; Rats; Rats, Wistar; Telmisartan | 2010 |
Telmisartan suppresses cerebral injury in a murine model of transient focal ischemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; Gliosis; Inflammation Mediators; Male; Mice; Mice, SCID; Nerve Degeneration; Neuroprotective Agents; PPAR gamma; Receptor, Angiotensin, Type 1; Reperfusion Injury; Telmisartan | 2010 |
Angiotensin AT1 receptor antagonists enhance the anticonvulsant action of valproate in the mouse model of maximal electroshock.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticonvulsants; Behavior, Animal; Benzimidazoles; Benzoates; Brain; Disease Models, Animal; Drug Synergism; Electroshock; Hypertension; Losartan; Male; Mice; Receptor, Angiotensin, Type 1; Seizures; Telmisartan; Valproic Acid | 2010 |
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice.
Topics: Abdominal Fat; Animals; Anti-Inflammatory Agents; Antigens, Differentiation; Benzimidazoles; Benzoates; CD3 Complex; Chemokine CXCL12; Chemotaxis; Dietary Fats; Disease Models, Animal; Inflammation; Insulin Resistance; Lymphocyte Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Rosiglitazone; T-Lymphocytes; Telmisartan; Thiazolidinediones; Time Factors | 2010 |
Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in zucker Fatty rats by suppressing advanced glycation end product receptor axis.
Topics: Animals; Benzimidazoles; Benzoates; Cyclohexanes; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Glycation End Products, Advanced; Humans; Insulin Resistance; Liver; Male; Nateglinide; Phenylalanine; Rats; Rats, Zucker; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Telmisartan | 2011 |
Telmisartan ameliorates experimental autoimmune myocarditis associated with inhibition of inflammation and oxidative stress.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Autoimmune Diseases; Benzimidazoles; Benzoates; Blotting, Western; Cytokines; Disease Models, Animal; Endomyocardial Fibrosis; Enzyme-Linked Immunosorbent Assay; Inflammation; Male; Myocarditis; Oxidative Stress; Rats; Rats, Inbred Lew; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan | 2011 |
Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hypertension; Kidney; Kidney Diseases; Kidney Glomerulus; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Telmisartan; Time Factors | 2011 |
Telmisartan improves nonalcoholic steatohepatitis in medaka (Oryzias latipes) by reducing macrophage infiltration and fat accumulation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Carnitine O-Palmitoyltransferase; Cell Movement; Disease Models, Animal; Fats; Fatty Liver; Gene Expression; Humans; Macrophages; Non-alcoholic Fatty Liver Disease; Oryzias; Oxidative Stress; PPAR gamma; Telmisartan; Weight Gain | 2011 |
Telmisartan provides better renal protection than valsartan in a rat model of metabolic syndrome.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Body Weight; Dietary Fats; Disease Models, Animal; Hypertension; Kidney Diseases; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Endoplasmic reticulum stress caused by left ventricular hypertrophy in rats: effects of telmisartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Disease Models, Animal; Endoplasmic Reticulum; Fibrosis; Hemodynamics; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Stress, Physiological; Telmisartan | 2011 |
Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anilides; Animals; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Obesity; PPAR gamma; Telmisartan | 2011 |
Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Apoptosis; Benzimidazoles; Benzoates; Biomarkers; Cytokines; Disease Models, Animal; Endoplasmic Reticulum; Heart Failure; Male; Mitogen-Activated Protein Kinases; Myocarditis; NADPH Oxidases; Oxidative Stress; Peptide Fragments; Peptidyl-Dipeptidase A; Protective Agents; Protein Subunits; Rats; Signal Transduction; Superoxides; Telmisartan | 2011 |
Adiponectin elevation by telmisartan ameliorates ischaemic myocardium in Zucker diabetic fatty rats with metabolic syndrome.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cardiotonic Agents; Disease Models, Animal; Heart; Immunohistochemistry; Metabolic Syndrome; Myocardial Reperfusion Injury; NF-kappa B; PPAR gamma; Rats; Rats, Zucker; Telmisartan; Troponin I; Tumor Necrosis Factor-alpha | 2012 |
Roles of interleukin 17 in angiotensin II type 1 receptor-mediated insulin resistance.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antibodies, Anti-Idiotypic; Benzimidazoles; Benzoates; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Insulin Resistance; Interleukin-17; Male; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Receptor, Angiotensin, Type 1; Telmisartan | 2012 |
Telmisartan acts through the modulation of ACE-2/ANG 1-7/mas receptor in rats with dilated cardiomyopathy induced by experimental autoimmune myocarditis.
Topics: Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blotting, Western; Cardiomyopathy, Dilated; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Gene Expression Regulation; Male; Myocarditis; Nervous System Autoimmune Disease, Experimental; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; Receptors, G-Protein-Coupled; Superoxides; Telmisartan | 2012 |
Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antibodies; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; Fibroblasts; Hepatocyte Growth Factor; Hydronephrosis; Kidney; Losartan; Male; Mice; Mice, Knockout; PPAR gamma; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Transforming Growth Factor beta; Ureteral Obstruction | 2012 |
Telmisartan inhibits vascular dysfunction and inflammation via activation of peroxisome proliferator-activated receptor-γ in subtotal nephrectomized rat.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta; Benzimidazoles; Benzoates; Blood Urea Nitrogen; Disease Models, Animal; Inflammation; Kidney Failure, Chronic; Losartan; Male; Malondialdehyde; Nephrectomy; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Vasodilation | 2012 |
Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Brain; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Encephalitis; Gene Expression Regulation; Lectins; Leukocyte Common Antigens; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; MPTP Poisoning; PPAR gamma; Receptor, Angiotensin, Type 1; Telmisartan; Tyrosine 3-Monooxygenase | 2012 |
Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Line, Tumor; Disease Models, Animal; Estrogen Receptor beta; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Androgen; Telmisartan; Tetrazoles | 2012 |
Effect of Telmisartan on local cardiovascular oxidative stress in mouse under chronic intermittent hypoxia condition.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Chronic Disease; Disease Models, Animal; Hypoxia; Male; Mice; Mice, Inbred Strains; Myocardium; NADPH Oxidases; Oxidative Stress; Reference Values; Sleep Apnea, Obstructive; Telmisartan | 2013 |
Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood-Brain Barrier; Blotting, Western; Cognition Disorders; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Losartan; Male; Maze Learning; Mice; Mice, Inbred C57BL; PPAR gamma; Random Allocation; Sensitivity and Specificity; Telmisartan | 2012 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Disease Models, Animal; Drug Partial Agonism; Fibrosis; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Stroke Volume; Telmisartan; Thiazolidinediones; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; C-Reactive Protein; Cardiomegaly; Creatine Kinase, MB Form; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Dyslipidemias; Hemodynamics; Injections, Intraperitoneal; Isoproterenol; Rats; Rats, Wistar; Spironolactone; Telmisartan; Treatment Outcome | 2012 |
Effect of angiotensin II receptor antagonist telmisartan on detrusor overactivity in rats with bladder outlet obstruction.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blotting, Western; Disease Models, Animal; Male; Nerve Growth Factor; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Telmisartan; Urinary Bladder Neck Obstruction; Urinary Bladder, Overactive | 2012 |
Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Benzimidazoles; Benzoates; Blotting, Western; Cardiac Catheterization; Catalase; Chemokine CCL2; Creatine Kinase, MB Form; Disease Models, Animal; Down-Regulation; Doxorubicin; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Heart Diseases; Inflammation Mediators; Intercellular Adhesion Molecule-1; L-Lactate Dehydrogenase; Macrophages; Male; Malondialdehyde; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; Telmisartan; Time Factors; Troponin I; Ventricular Function, Left; Vitamin E | 2012 |
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biomarkers; Blood Glucose; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Guanylate Cyclase; Kidney Function Tests; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Organ Size; Pyrazoles; Pyrimidines; Receptors, Angiotensin; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan | 2012 |
Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin-related kinase B in hippocampus of hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Brain-Derived Neurotrophic Factor; Cognition Disorders; Disease Models, Animal; Hippocampus; Hypertension; Male; PPAR gamma; Protein Kinases; Rats, Inbred SHR; Receptor, trkB; Telmisartan; Up-Regulation | 2012 |
Telmisartan attenuates hepatic fibrosis in bile duct-ligated rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Benzimidazoles; Benzoates; Bile Ducts; Blotting, Western; Disease Models, Animal; Immunohistochemistry; Ligation; Liver Cirrhosis; Male; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Telmisartan | 2012 |
Effect of angiotensin II receptor blocker on experimental periodontitis in a mouse model of Marfan syndrome.
Topics: Alveolar Bone Loss; Angiotensin Receptor Antagonists; Animals; Bacteroidaceae Infections; Benzimidazoles; Benzoates; Bone Resorption; Disease Models, Animal; Inflammation; Interleukin-17; Male; Marfan Syndrome; Mice; Osteoclasts; Periodontitis; Porphyromonas gingivalis; Telmisartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2013 |
Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.
Topics: Adipocytes; Administration, Oral; AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Benzimidazoles; Benzoates; Cell Line; Diabetes Mellitus; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Fatty Acid Transport Proteins; Glucose Transporter Type 4; Hypertrophy; Insulin; Islets of Langerhans; Male; Mice; Muscle Fibers, Skeletal; Muscle, Skeletal; NAD; Obesity; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; PPAR gamma; RNA, Messenger; Signal Transduction; Sirtuin 1; Telmisartan; Time Factors; Trans-Activators; Transcription Factors | 2012 |
DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dipeptidyl Peptidase 4; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Linagliptin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nitric Oxide Synthase Type III; Oxidative Stress; Purines; Quinazolines; Streptozocin; Telmisartan; Treatment Outcome | 2012 |
Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: new insights into mechanisms.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Blood Pressure; Cell Dedifferentiation; Cell Line; Chemokine CCL20; Cytoprotection; Disease Models, Animal; Fibrosis; Gene Expression Profiling; Gene Expression Regulation; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Humans; Hydralazine; Hydrochlorothiazide; Hypertension; Inflammation; Isoantibodies; Macrophages; Male; Mice; Nephrectomy; Podocytes; Proteinuria; Rats; Rats, Wistar; Receptors, CCR6; Receptors, Platelet-Derived Growth Factor; RNA Interference; RNA, Messenger; Telmisartan; Time Factors; Transfection | 2013 |
Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors.
Topics: Alzheimer Disease; Amyloid; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Brain Ischemia; Cerebrovascular Disorders; Cerebrum; Disease Models, Animal; Dose-Response Relationship, Drug; Hippocampus; Inflammation; Male; Maze Learning; Memory; Memory Disorders; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Tumor Necrosis Factor-alpha | 2012 |
Telmisartan plus propranolol improves liver fibrosis and bile duct proliferation in the PSC-like Abcb4-/- mouse model.
Topics: Adrenergic beta-Antagonists; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzimidazoles; Benzoates; Bile Ducts; Cholangitis, Sclerosing; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Liver; Mice; Mice, Inbred BALB C; Mice, Knockout; Myofibroblasts; Propranolol; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan | 2013 |
Angiotensin blockade prevents type 2 diabetes by formation of fat cells.
Topics: Adipocytes; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cell Differentiation; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Telmisartan | 2002 |
The metabolic effects of angiotensin-receptor blockers.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Cells, Cultured; Disease Models, Animal; DNA, Complementary; Gene Expression; Male; Metabolic Syndrome; Mice; Polymerase Chain Reaction; PPAR gamma; Rats; Rats, Sprague-Dawley; Telmisartan | 2005 |
Suppression of ocular inflammation in endotoxin-induced uveitis by blocking the angiotensin II type 1 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aqueous Humor; Benzimidazoles; Benzoates; Blotting, Western; Cell Adhesion; Disease Models, Animal; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Escherichia coli; Eye Proteins; Immunoenzyme Techniques; Intercellular Adhesion Molecule-1; Leukocytes; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Retinal Vessels; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Telmisartan; Up-Regulation; Uveitis | 2005 |
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Drug Therapy, Combination; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-6; Macrophages; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Monocytes; Pyrroles; Ramipril; Renin-Angiotensin System; Telmisartan | 2005 |
Telmisartan inhibits both oxidative stress and renal fibrosis after unilateral ureteral obstruction in acatalasemic mice.
Topics: Acatalasia; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Fibrosis; Immunohistochemistry; In Situ Nick-End Labeling; Kidney; Kidney Diseases; Lipid Peroxidation; Male; Mice; Mice, Inbred C3H; Mice, Mutant Strains; NADPH Oxidases; Oxidative Stress; Telmisartan; Treatment Outcome; Ureteral Obstruction | 2005 |
Telmisartan attenuates chronic ciclosporin A nephrotoxicity in a pig model.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biopsy; Blood Flow Velocity; Blood Pressure; Cyclosporine; Disease Models, Animal; Female; Follow-Up Studies; Glomerular Filtration Rate; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Magnetic Resonance Imaging; Renal Circulation; Swine; Telmisartan; Treatment Outcome | 2007 |
Neuroprotective effects of angiotensin II type 1 receptor (AT1R) blocker, telmisartan, via modulating AT1R and AT2R signaling in retinal inflammation.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Dark Adaptation; Disease Models, Animal; Electroretinography; Fluorescent Antibody Technique, Indirect; Glial Fibrillary Acidic Protein; Immunoblotting; Lipopolysaccharides; Mice; Mice, Inbred C57BL; Neuroglia; Neuroprotective Agents; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Retina; Rhodopsin; STAT3 Transcription Factor; Synaptophysin; Telmisartan; Uveitis | 2006 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Calcium Channel Blockers; Cell Size; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Intra-Abdominal Fat; Male; Obesity; PPAR gamma; Random Allocation; Rats; Rats, Long-Evans; Telmisartan; Tetrazoles; Valine; Valsartan | 2007 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
Renoprotective effects of telmisartan in the 5/6 nephrectomised rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Kidney; Nephrectomy; Rats; Telmisartan | 2007 |
Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Hypertension; Hypoglycemic Agents; Insulin Resistance; Male; PPAR gamma; Rats; Rats, Inbred SHR; Telmisartan | 2007 |
Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Aorta; Benzimidazoles; Benzoates; Chemokine CCL2; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension; Losartan; Macrophages; Male; Mice; Monocytes; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, CCR2; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan | 2007 |
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Drug Therapy, Combination; Hypertension, Malignant; Male; Mineralocorticoid Receptor Antagonists; Nephrosclerosis; NG-Nitroarginine Methyl Ester; PPAR gamma; Rats; Rats, Inbred SHR; RNA, Messenger; Spironolactone; Telmisartan; Transforming Growth Factor beta1 | 2007 |
Cardiovascular reactivity after blockade of angiotensin AT1 receptors in the experimental model of tilting test in conscious rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Pressure; Disease Models, Animal; Dose-Response Relationship, Drug; Hypotension, Orthostatic; Losartan; Male; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Stress, Physiological; Telmisartan | 2008 |
Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Topics: Acetylcholine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Carotid Arteries; Disease Models, Animal; Hypertension; Male; NADPH Oxidases; Peptidyl-Dipeptidase A; PPAR gamma; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Telmisartan; Tetrazoles; Valine; Valsartan; Vasodilation; Vasodilator Agents | 2007 |
Bladder angiotensin-II receptors: characterization and alteration in bladder outlet obstruction.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Female; Male; Organ Size; Rats; Rats, Sprague-Dawley; Telmisartan; Urinary Bladder; Urinary Bladder Neck Obstruction | 2009 |
Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta, Abdominal; Aorta, Thoracic; Atherosclerosis; Benzimidazoles; Benzoates; Biphenyl Compounds; Disease Models, Animal; Hyperlipidemias; Male; Nitric Oxide; PPAR gamma; Rabbits; Telmisartan; Tetrazoles; Up-Regulation | 2008 |
[An experimental study of expression of angiotension converting enzyme 2 in myocardium and effect of telmisartan treatment in pressure-overloaded rats].
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Aortic Coarctation; Benzimidazoles; Benzoates; Disease Models, Animal; Male; Myocardium; Peptidyl-Dipeptidase A; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Telmisartan | 2008 |
Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Collagen Type I; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Hypertension; Hypertrophy, Left Ventricular; Male; Myocardium; NADPH Oxidases; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Plasminogen Activator Inhibitor 1; PPAR gamma; Protein Kinase C; Protein Kinase Inhibitors; Rats; Rats, Inbred Dahl; Research Design; rho-Associated Kinases; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sodium Chloride, Dietary; Superoxides; Telmisartan; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2008 |